Individualized Hormone Replacement Therapy Versus Ovarian Transplantation
Received Date: February 09, 2019; Published Date: February 12, 2019
Numerous studies conclude that risks and benefits of hormonal replacement therapy (HRT) are dose-dependent . The pharmaceutical industry attempted to partially resolve the issue of individualization of HRT by manufacturing at least six different types of Minivelle patches (0.024mg, 0.0375mg, 0.05mg, 0.075mg, and 0.1mg). The choices offered by the pharmaceuticals are useful but fail to caliber dose based on the needs of the individual patient.